1
|
Yao M, Wu M, Yuan M, Wu M, Shen A, Chen Y, Lian D, Liu X, Peng J. Enhancing the therapeutic potential of isoliensinine for hypertension through PEG-PLGA nanoparticle delivery: A comprehensive in vivo and in vitro study. Biomed Pharmacother 2024; 174:116541. [PMID: 38565063 DOI: 10.1016/j.biopha.2024.116541] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2024] [Revised: 03/29/2024] [Accepted: 03/29/2024] [Indexed: 04/04/2024] Open
Abstract
BACKGROUND Hypertension, a highly prevalent chronic disease, is known to inflict severe damage upon blood vessels. In our previous study, isoliensinine, a kind of bibenzyl isoquinoline alkaloid which isolated from a TCM named Lotus Plumule (Nelumbo nucifera Gaertn), exhibits antihypertensive and vascular smooth muscle proliferation-inhibiting effects, but its application is limited due to poor water solubility and low bioavailability. In this study, we proposed to prepare isoliensinine loaded by PEG-PLGA polymer nanoparticles to increase its efficacy METHOD: We synthesized and thoroughly characterized PEG-PLGA nanoparticles loaded with isoliensinine using a nanoprecipitation method, denoted as, PEG-PLGA@Isoliensinine. Additionally, we conducted comprehensive investigations into the stability of PEG-PLGA@Isoliensinine, in vitro drug release profiles, and in vivo pharmacokinetics. Furthermore, we assessed the antihypertensive efficacy of this nano-system through in vitro experiments on A7R5 cells and in vivo studies using AngII-induced mice. RESULT The findings reveal that PEG-PLGA@Isoliensinine significantly improves isoliensinine absorption by A7R5 cells and enhances targeted in vivo distribution. This translates to a more effective reduction of AngII-induced hypertension and vascular smooth muscle proliferation. CONCLUSION In this study, we successfully prepared PEG-PLGA@Isoliensinine by nano-precipitation, and we confirmed that PEG-PLGA@Isoliensinine surpasses free isoliensinine in its effectiveness for the treatment of hypertension, as demonstrated through both in vivo and in vitro experiments. SIGNIFICANCE This study lays the foundation for isoliensinine's clinical use in hypertension treatment and vascular lesion protection, offering new insights for enhancing the bioavailability of traditional Chinese medicine components. Importantly, no toxicity was observed, affirming the successful implementation of this innovative drug delivery system in vivo and offers a promising strategy for enhancing the effectiveness of Isoliensinine and propose an innovative avenue for developing novel formulations of traditional Chinese medicine monomers.
Collapse
Affiliation(s)
- Mengying Yao
- Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350122, China; Fujian Key Laboratory of Integrative Medicine on Geriatrics, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350122, China; Fujian Collaborative Innovation Center for Integrative Medicine in Prevention and Treatment of Major Chronic Cardiovascular Diseases, Fuzhou, Fujian 350122, China
| | - Ming Wu
- The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou 350025, PR China
| | - Meng Yuan
- Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350122, China; Fujian Key Laboratory of Integrative Medicine on Geriatrics, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350122, China
| | - Meizhu Wu
- Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350122, China; Fujian Key Laboratory of Integrative Medicine on Geriatrics, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350122, China; Fujian Collaborative Innovation Center for Integrative Medicine in Prevention and Treatment of Major Chronic Cardiovascular Diseases, Fuzhou, Fujian 350122, China
| | - Aling Shen
- Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350122, China; Fujian Key Laboratory of Integrative Medicine on Geriatrics, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350122, China; Fujian Collaborative Innovation Center for Integrative Medicine in Prevention and Treatment of Major Chronic Cardiovascular Diseases, Fuzhou, Fujian 350122, China; Innovation and Transformation Center, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350122, China
| | - Youqin Chen
- Department of Pediatrics,Case Western Reserve University School of Medicine,Rainbow Babies and Children's Hospital, Cleveland, OH, USA
| | - Dawei Lian
- Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350122, China; Fujian Key Laboratory of Integrative Medicine on Geriatrics, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350122, China; Fujian Collaborative Innovation Center for Integrative Medicine in Prevention and Treatment of Major Chronic Cardiovascular Diseases, Fuzhou, Fujian 350122, China.
| | - Xiaolong Liu
- The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou 350025, PR China.
| | - Jun Peng
- Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350122, China; Fujian Key Laboratory of Integrative Medicine on Geriatrics, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350122, China; Fujian Collaborative Innovation Center for Integrative Medicine in Prevention and Treatment of Major Chronic Cardiovascular Diseases, Fuzhou, Fujian 350122, China.
| |
Collapse
|
2
|
Muema JM, Mutunga JM, Obonyo MA, Getahun MN, Mwakubambanya RS, Akala HM, Cheruiyot AC, Yeda RA, Juma DW, Andagalu B, Johnson JL, Roth AL, Bargul JL. Isoliensinine from Cissampelos pariera rhizomes exhibits potential gametocytocidal and anti-malarial activities against Plasmodium falciparum clinical isolates. Malar J 2023; 22:161. [PMID: 37208735 DOI: 10.1186/s12936-023-04590-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2022] [Accepted: 05/15/2023] [Indexed: 05/21/2023] Open
Abstract
BACKGROUND The unmet demand for effective malaria transmission-blocking agents targeting the transmissible stages of Plasmodium necessitates intensive discovery efforts. In this study, a bioactive bisbenzylisoquinoline (BBIQ), isoliensinine, from Cissampelos pariera (Menispermaceae) rhizomes was identified and characterized for its anti-malarial activity. METHODS Malaria SYBR Green I fluorescence assay was performed to evaluate the in vitro antimalarial activity against D6, Dd2, and F32-ART5 clones, and immediate ex vivo (IEV) susceptibility for 10 freshly collected P. falciparum isolates. To determine the speed- and stage-of-action of isoliensinine, an IC50 speed assay and morphological analyses were performed using synchronized Dd2 asexuals. Gametocytocidal activity against two culture-adapted gametocyte-producing clinical isolates was determined using microscopy readouts, with possible molecular targets and their binding affinities deduced in silico. RESULTS Isoliensinine displayed a potent in vitro gametocytocidal activity at mean IC50gam values ranging between 0.41 and 0.69 µM for Plasmodium falciparum clinical isolates. The BBIQ compound also inhibited asexual replication at mean IC50Asexual of 2.17 µM, 2.22 µM, and 2.39 µM for D6, Dd2 and F32-ART5 respectively, targeting the late-trophozoite to schizont transition. Further characterization demonstrated a considerable immediate ex vivo potency against human clinical isolates at a geometric mean IC50IEV = 1.433 µM (95% CI 0.917-2.242). In silico analyses postulated a probable anti-malarial mechanism of action by high binding affinities for four mitotic division protein kinases; Pfnek1, Pfmap2, Pfclk1, and Pfclk4. Additionally, isoliensinine was predicted to possess an optimal pharmacokinetics profile and drug-likeness properties. CONCLUSION These findings highlight considerable grounds for further exploration of isoliensinine as an amenable scaffold for malaria transmission-blocking chemistry and target validation.
Collapse
Affiliation(s)
- Jackson M Muema
- Department of Biochemistry, Jomo Kenyatta University of Agriculture and Technology (JKUAT), Nairobi, Kenya.
- U.S. Army Medical Research Directorate-Africa (USAMRD-A), Centre for Global Health Research (CGHR), Kenya Medical Research Institute (KEMRI), Kisumu, Kenya.
| | - James M Mutunga
- U.S. Army Medical Research Directorate-Africa (USAMRD-A), Centre for Global Health Research (CGHR), Kenya Medical Research Institute (KEMRI), Kisumu, Kenya
- Department of Biological Sciences, School of Pure and Applied Sciences, Mount Kenya University, Thika, Kenya
- School of Engineering Design, Technology and Professional Programs, Pennsylvania State University, University Park, PA, 16802, USA
| | - Meshack A Obonyo
- Department of Biochemistry and Molecular Biology, Egerton University, Egerton, Kenya
| | - Merid N Getahun
- International Centre of Insect Physiology and Ecology (Icipe), Nairobi, Kenya
| | | | - Hoseah M Akala
- U.S. Army Medical Research Directorate-Africa (USAMRD-A), Centre for Global Health Research (CGHR), Kenya Medical Research Institute (KEMRI), Kisumu, Kenya
| | - Agnes C Cheruiyot
- U.S. Army Medical Research Directorate-Africa (USAMRD-A), Centre for Global Health Research (CGHR), Kenya Medical Research Institute (KEMRI), Kisumu, Kenya
| | - Redemptah A Yeda
- U.S. Army Medical Research Directorate-Africa (USAMRD-A), Centre for Global Health Research (CGHR), Kenya Medical Research Institute (KEMRI), Kisumu, Kenya
| | - Dennis W Juma
- U.S. Army Medical Research Directorate-Africa (USAMRD-A), Centre for Global Health Research (CGHR), Kenya Medical Research Institute (KEMRI), Kisumu, Kenya
| | - Ben Andagalu
- U.S. Army Medical Research Directorate-Africa (USAMRD-A), Centre for Global Health Research (CGHR), Kenya Medical Research Institute (KEMRI), Kisumu, Kenya
| | - Jaree L Johnson
- U.S. Army Medical Research Directorate-Africa (USAMRD-A), Centre for Global Health Research (CGHR), Kenya Medical Research Institute (KEMRI), Kisumu, Kenya
| | - Amanda L Roth
- U.S. Army Medical Research Directorate-Africa (USAMRD-A), Centre for Global Health Research (CGHR), Kenya Medical Research Institute (KEMRI), Kisumu, Kenya
| | - Joel L Bargul
- Department of Biochemistry, Jomo Kenyatta University of Agriculture and Technology (JKUAT), Nairobi, Kenya.
- International Centre of Insect Physiology and Ecology (Icipe), Nairobi, Kenya.
| |
Collapse
|
3
|
Deng W, Li H, Zhang Y, Lin Y, Chen C, Chen J, Huang Y, Zhou Y, Tang Y, Ding J, Yuan K, Xu L, Li Y, Zhang S. Isoliensinine suppresses bone loss by targeted inhibition of RANKL-RANK binding. Biochem Pharmacol 2023; 210:115463. [PMID: 36849060 DOI: 10.1016/j.bcp.2023.115463] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2023] [Revised: 02/18/2023] [Accepted: 02/21/2023] [Indexed: 02/27/2023]
Abstract
BACKGROUND Osteoporosis, a systemic metabolic bone disease, is often caused by the disruption of dynamic equilibrium between osteoclasts and osteoblasts. Overactive bone resorption, in which osteoclasts play a major role, is one of the most common and major causes of osteoporosis. Less costly and more effective drug treatments for this disease are needed. Based on the combination of molecular docking techniques and in vitro cell assays, this study aimed to explore the mechanism by which Isoliensinine (ILS) protects the bone loss by inhibiting osteoclast differentiation. METHODS A virtual docking model based on molecular docking technology was used to investigate the interactions between ILS and the Receptor Activator of Nuclear Kappa-B (RANK)/Receptor Activator of Nuclear Kappa-B Ligand (RANKL).In this study, we determined the effective dose of action of ILS to inhibit osteoclast differentiation in vitro and, using bone resorption experiments, RT-CPR and Western Blot investigated the effects of ILS on bone resorption function and normal expression of osteoclast-associated genes and proteins, and validated potential mechanistic pathways. In vivo experiments revealed that ILS could inhibit bone loss through Micro-CT results. Finally, the molecular interaction between ILS and RANK/RANKL was investigated using biomolecular interaction experiments to verify the correctness and accuracy of the computational results. RESULTS ILS binds to RANK and RANKL proteins, respectively, through virtual molecular docking. The Surface Plasmon Resonance (SPR) experiment results revealed that phosphorylated JNK, ERK, P38, and P65 expression was significantly downregulated when ILS were targeted to inhibit RANKL/RANK binding. At the same time, the expression of IKB-a was significantly increased under the stimulation of ILS, which rescued the degradation of IKB-a. ILS can significantly inhibit the levels of Reactive Oxygen Species (ROS) and Ca2 + concentration in vitro. Finally, the results of Micro-CT showed that ILS can significantly inhibit bone loss in vivo, indicating that ILS has a potential role in the treatment of osteoporosis. CONCLUSION ILS inhibits osteoclast differentiation and bone loss by preventing the normal binding of RANKL/RANK, affecting downstream signaling pathways, including MAPK.NF-KB, ROS, Ca2+, genes, and proteins.
Collapse
Affiliation(s)
- Wei Deng
- No. 12, Guangzhou University of Chinese Medicine, Ji Chang Road, Baiyun District, Guangzhou City, Guangdong Province 510405, China; The Laboratory of Orthopaedics and Traumatology of Lingnan Medical Research Center, Guangzhou University of Chinese Medicine, 12 Jichang Road, Baiyun District, Guangzhou 510405, China; The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, No. 12 Airport Road, Baiyun District, Guangzhou City, Guangdong Province 510405, China
| | - HaiShan Li
- No. 12, Guangzhou University of Chinese Medicine, Ji Chang Road, Baiyun District, Guangzhou City, Guangdong Province 510405, China; The Laboratory of Orthopaedics and Traumatology of Lingnan Medical Research Center, Guangzhou University of Chinese Medicine, 12 Jichang Road, Baiyun District, Guangzhou 510405, China; The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, No. 12 Airport Road, Baiyun District, Guangzhou City, Guangdong Province 510405, China
| | - YaYa Zhang
- No. 12, Guangzhou University of Chinese Medicine, Ji Chang Road, Baiyun District, Guangzhou City, Guangdong Province 510405, China; The Laboratory of Orthopaedics and Traumatology of Lingnan Medical Research Center, Guangzhou University of Chinese Medicine, 12 Jichang Road, Baiyun District, Guangzhou 510405, China; School of Basic Medical Sciences, Guangzhou University of Chinese Medicine, Guangdong Province 510405, China
| | - YueWei Lin
- No. 12, Guangzhou University of Chinese Medicine, Ji Chang Road, Baiyun District, Guangzhou City, Guangdong Province 510405, China; The Laboratory of Orthopaedics and Traumatology of Lingnan Medical Research Center, Guangzhou University of Chinese Medicine, 12 Jichang Road, Baiyun District, Guangzhou 510405, China; The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, No. 12 Airport Road, Baiyun District, Guangzhou City, Guangdong Province 510405, China
| | - ChiWei Chen
- The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, No. 12 Airport Road, Baiyun District, Guangzhou City, Guangdong Province 510405, China
| | - JunChun Chen
- Guangxi University of Chinese Medicine, No. 179, Mingxiu East Road, Nanning City, Guangxi Province 530200, China
| | - YanBo Huang
- No. 12, Guangzhou University of Chinese Medicine, Ji Chang Road, Baiyun District, Guangzhou City, Guangdong Province 510405, China; The Laboratory of Orthopaedics and Traumatology of Lingnan Medical Research Center, Guangzhou University of Chinese Medicine, 12 Jichang Road, Baiyun District, Guangzhou 510405, China; The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, No. 12 Airport Road, Baiyun District, Guangzhou City, Guangdong Province 510405, China
| | - Yi Zhou
- Guangxi Medical University, No. 22, Shuangyong Road, Qingxiu District, Nanning City, Guangxi Province 530021, China
| | - YongChao Tang
- No. 12, Guangzhou University of Chinese Medicine, Ji Chang Road, Baiyun District, Guangzhou City, Guangdong Province 510405, China; The Laboratory of Orthopaedics and Traumatology of Lingnan Medical Research Center, Guangzhou University of Chinese Medicine, 12 Jichang Road, Baiyun District, Guangzhou 510405, China; The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, No. 12 Airport Road, Baiyun District, Guangzhou City, Guangdong Province 510405, China
| | - JinYong Ding
- No. 12, Guangzhou University of Chinese Medicine, Ji Chang Road, Baiyun District, Guangzhou City, Guangdong Province 510405, China; The Laboratory of Orthopaedics and Traumatology of Lingnan Medical Research Center, Guangzhou University of Chinese Medicine, 12 Jichang Road, Baiyun District, Guangzhou 510405, China
| | - Kai Yuan
- No. 12, Guangzhou University of Chinese Medicine, Ji Chang Road, Baiyun District, Guangzhou City, Guangdong Province 510405, China; The Laboratory of Orthopaedics and Traumatology of Lingnan Medical Research Center, Guangzhou University of Chinese Medicine, 12 Jichang Road, Baiyun District, Guangzhou 510405, China; The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, No. 12 Airport Road, Baiyun District, Guangzhou City, Guangdong Province 510405, China
| | - LiangLiang Xu
- No. 12, Guangzhou University of Chinese Medicine, Ji Chang Road, Baiyun District, Guangzhou City, Guangdong Province 510405, China; The Laboratory of Orthopaedics and Traumatology of Lingnan Medical Research Center, Guangzhou University of Chinese Medicine, 12 Jichang Road, Baiyun District, Guangzhou 510405, China; The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, No. 12 Airport Road, Baiyun District, Guangzhou City, Guangdong Province 510405, China.
| | - YongXian Li
- No. 12, Guangzhou University of Chinese Medicine, Ji Chang Road, Baiyun District, Guangzhou City, Guangdong Province 510405, China; The Laboratory of Orthopaedics and Traumatology of Lingnan Medical Research Center, Guangzhou University of Chinese Medicine, 12 Jichang Road, Baiyun District, Guangzhou 510405, China; The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, No. 12 Airport Road, Baiyun District, Guangzhou City, Guangdong Province 510405, China.
| | - ShunCong Zhang
- No. 12, Guangzhou University of Chinese Medicine, Ji Chang Road, Baiyun District, Guangzhou City, Guangdong Province 510405, China; The Laboratory of Orthopaedics and Traumatology of Lingnan Medical Research Center, Guangzhou University of Chinese Medicine, 12 Jichang Road, Baiyun District, Guangzhou 510405, China; The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, No. 12 Airport Road, Baiyun District, Guangzhou City, Guangdong Province 510405, China.
| |
Collapse
|
4
|
Lv Y, Wang S, Wang Y, Zhang X, Jia Q, Han S, He L. Construction and application of covalently bonded CD147 cell membrane chromatography model based on polystyrene microspheres. Anal Bioanal Chem 2023; 415:1371-1383. [PMID: 36651973 DOI: 10.1007/s00216-023-04528-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2022] [Revised: 12/19/2022] [Accepted: 01/05/2023] [Indexed: 01/19/2023]
Abstract
In this study, a novel cell membrane chromatography (CMC) model was developed to investigate cluster of differentiation 147 (CD147) targeted anti-tumor drug leads for specific screening and ligand-receptor interaction analysis by SNAP-tagged CD147 fusion protein conjugation and polystyrene microspheres (PS) modification. Traditional Chinese medicines (TCMs) are widely used in the treatment of cancer. CD147 plays important roles in tumor progression and acts as an attractive target for therapeutic intervention; therapeutic drugs for CD147-related cancers are limited to date. Thus, a screening method for active components in TCMs is crucial for the further research and development of CD147 antagonists. However, improvement is still needed to perform specific and accurate drug lead screening using the CMC-based method. Recently, our group developed a covalently immobilized receptor-SNAP-tag/CMC model using silica gel as carrier. Besides the carboxyl group on multi-step modified silica particles, the amino group of benzyl-guanine (BG, substrate of SNAP-tag) also possesses reactivity towards the carboxyl group on available carboxyl-modified PS. Herein, we used PS as carrier and an extended SNAP-tag with CD147 receptor to construct the PS-BG-CD147/CMC model for active compound investigation coupled with HPLC/MS and applied this coupled PS-BG-CD147/CMC-HPLC/MS two-dimensional system to drug lead screening from Nelumbinis Plumula extract (NPE) sample. In addition, to comprehensively verify the pharmacological effects of screened ingredients, a cell proliferation inhibition assay was performed, and the interaction between the ingredients and CD147 was studied by the frontal analysis method. This study developed a high-throughput PS-based CMC screening platform, which could be widely applied and utilized in chromatographic separation and drug lead discovery.
Collapse
Affiliation(s)
- Yanni Lv
- School of Pharmacy, Xi'an Jiaotong University, 76# Yanta Westroad, Xi'an, Shaanxi, 710061, People's Republic of China
- Institute of Pharmaceutical Science and Technology, Western China Science &Technology Innovation Harbour, Xi'an, Shaanxi, 710115, People's Republic of China
| | - Saisai Wang
- School of Pharmacy, Xi'an Jiaotong University, 76# Yanta Westroad, Xi'an, Shaanxi, 710061, People's Republic of China
- Institute of Pharmaceutical Science and Technology, Western China Science &Technology Innovation Harbour, Xi'an, Shaanxi, 710115, People's Republic of China
- Jiangsu Chia Tai-Tianqing Pharmaceutical Co., Ltd. Lianyungang, Jiangsu, 222062, People's Republic of China
| | - Yamin Wang
- School of Pharmacy, Xi'an Jiaotong University, 76# Yanta Westroad, Xi'an, Shaanxi, 710061, People's Republic of China
- Institute of Pharmaceutical Science and Technology, Western China Science &Technology Innovation Harbour, Xi'an, Shaanxi, 710115, People's Republic of China
| | - Xin Zhang
- School of Pharmacy, Xi'an Jiaotong University, 76# Yanta Westroad, Xi'an, Shaanxi, 710061, People's Republic of China
- Institute of Pharmaceutical Science and Technology, Western China Science &Technology Innovation Harbour, Xi'an, Shaanxi, 710115, People's Republic of China
| | - Qianqian Jia
- School of Pharmacy, Xi'an Jiaotong University, 76# Yanta Westroad, Xi'an, Shaanxi, 710061, People's Republic of China
- Institute of Pharmaceutical Science and Technology, Western China Science &Technology Innovation Harbour, Xi'an, Shaanxi, 710115, People's Republic of China
| | - Shengli Han
- School of Pharmacy, Xi'an Jiaotong University, 76# Yanta Westroad, Xi'an, Shaanxi, 710061, People's Republic of China.
- Institute of Pharmaceutical Science and Technology, Western China Science &Technology Innovation Harbour, Xi'an, Shaanxi, 710115, People's Republic of China.
| | - Langchong He
- School of Pharmacy, Xi'an Jiaotong University, 76# Yanta Westroad, Xi'an, Shaanxi, 710061, People's Republic of China
- Institute of Pharmaceutical Science and Technology, Western China Science &Technology Innovation Harbour, Xi'an, Shaanxi, 710115, People's Republic of China
| |
Collapse
|
5
|
Liu Z, Hu L, Zhang Z, Song L, Zhang P, Cao Z, Ma J. Isoliensinine Eliminates Afterdepolarizations Through Inhibiting Late Sodium Current and L-Type Calcium Current. Cardiovasc Toxicol 2020; 21:67-78. [PMID: 32770463 DOI: 10.1007/s12012-020-09597-z] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/05/2020] [Accepted: 08/01/2020] [Indexed: 12/19/2022]
Abstract
Isoliensinine (IL) extracted from lotus seed has a good therapeutic effect on cardiovascular diseases. However, its effect on ion channels of ventricular myocytes is still unclear. We used whole-cell patch-clamp techniques to detect the effects of IL on transmembrane ion currents and action potential (AP) in isolated rabbit left ventricular myocytes. IL inhibited the transient sodium current (INaT), late sodium current (INaL) enlarged by sea anemone toxin (ATX II) and L-type calcium current (ICaL) in a concentration-dependent manner without affecting inward rectifier potassium current (IK1) and delayed rectifier potassium current (IK). These inhibitory effects are mainly manifested as reduced the AP amplitude (APA) and maximum depolarization velocity (Vmax) and shortened the action potential duration (APD), but had no significant effect on the resting membrane potential (RMP). Moreover, IL significantly eliminated ATX II-induced early afterdepolarizations (EADs) and high extracellular calcium-induced delayed afterdepolarizations (DADs). These results revealed that IL effectively eliminated EADs and DADs through inhibiting INaL and ICaL in ventricular myocytes, which indicates it has potential antiarrhythmic action.
Collapse
Affiliation(s)
- Zhipei Liu
- Cardio-Electrophysiological Research Laboratory, Medical College of Wuhan University of Science and Technology, Hongshan District, Wuhan, 430065, China.,Hubei Province Key Laboratory of Occupational Hazard Identification and Control, Medical College of Wuhan University of Science and Technology, Wuhan, 430065, China
| | - Liangkun Hu
- Tianyou Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, 430065, China
| | - Zefu Zhang
- Cardio-Electrophysiological Research Laboratory, Medical College of Wuhan University of Science and Technology, Hongshan District, Wuhan, 430065, China.,Hubei Province Key Laboratory of Occupational Hazard Identification and Control, Medical College of Wuhan University of Science and Technology, Wuhan, 430065, China
| | - Lv Song
- Cardio-Electrophysiological Research Laboratory, Medical College of Wuhan University of Science and Technology, Hongshan District, Wuhan, 430065, China
| | - Peihua Zhang
- Cardio-Electrophysiological Research Laboratory, Medical College of Wuhan University of Science and Technology, Hongshan District, Wuhan, 430065, China
| | - Zhenzhen Cao
- Cardio-Electrophysiological Research Laboratory, Medical College of Wuhan University of Science and Technology, Hongshan District, Wuhan, 430065, China
| | - Jihua Ma
- Cardio-Electrophysiological Research Laboratory, Medical College of Wuhan University of Science and Technology, Hongshan District, Wuhan, 430065, China. .,Hubei Province Key Laboratory of Occupational Hazard Identification and Control, Medical College of Wuhan University of Science and Technology, Wuhan, 430065, China.
| |
Collapse
|
6
|
Hu G, Xu RA, Dong YY, Wang YY, Yao WW, Chen ZC, Chen D, Bu T, Ge RS. Simultaneous determination of liensinine, isoliensinine and neferine in rat plasma by UPLC-MS/MS and application of the technique to pharmacokinetic studies. J Ethnopharmacol 2015; 163:94-8. [PMID: 25636663 DOI: 10.1016/j.jep.2015.01.020] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/03/2014] [Revised: 01/10/2015] [Accepted: 01/15/2015] [Indexed: 05/08/2023]
Abstract
ETHNOPHARMACOLOGICAL RELEVANCE The in vivo effects of traditional herbal medicines are generally mediated by multiple bioactive components. The main constituents of Lotus Plumule are alkaloids such as liensinine, isoliensinine and neferine. In this study, a simple, sensitive, and robust analytical method based on ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) has been developed for the determination of the three alkaloids in rat plasma using carbamazepine as internal standard (IS). MATERIALS AND METHODS After precipitation of the proteins with acetonitrile, chromatography was performed on an Acquity UPLC BEH C18 column (2.1mm×50mm, 1.7μm particle size) using a gradient elution with 0.1% formic acid in water and acetonitrile. Mass spectrometry involved positive electrospray ionization and multiple reaction monitoring (MRM) of the transitions at m/z 611.7→206.2 for liensinine, 611.3→192.2 for isoliensinine, 625.2→206.1 for neferine and m/z 237.1→194.2 for IS. RESULTS The method was linear over the concentration range 5-1000ng/mL with a lower limit of quantifof 5ng/mL for each alkaloid. Inter- and intra-day precision (RSD%) were all within 11.4% and the accuracy (RE%) were equal or lower than 10.4%. Recoveries were more than 75.3% and matrix effects were not significant. Stability studies showed that the three alkaloids were stable under a variety of storage conditions. CONCLUSION The method was successfully applied to a pharmacokinetic study involving intravenous administration of liensinine, isoliensinine and neferine to rats.
Collapse
Affiliation(s)
- Guoxin Hu
- School of Pharmacy, Wenzhou Medical University, Wenzhou 325035, China
| | - Ren-ai Xu
- The Second Affiliated Hospital & Yuying Children׳s Hospital of Wenzhou Medical University, Wenzhou 325027, China; The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China
| | - Yao-yao Dong
- School of Pharmacy, Wenzhou Medical University, Wenzhou 325035, China
| | - Yi-yan Wang
- The Second Affiliated Hospital & Yuying Children׳s Hospital of Wenzhou Medical University, Wenzhou 325027, China
| | - Wen-wen Yao
- School of Pharmacy, Wenzhou Medical University, Wenzhou 325035, China
| | - Zhi-chuan Chen
- The Second Affiliated Hospital & Yuying Children׳s Hospital of Wenzhou Medical University, Wenzhou 325027, China
| | - Dongxin Chen
- The Second Affiliated Hospital & Yuying Children׳s Hospital of Wenzhou Medical University, Wenzhou 325027, China
| | - Tiao Bu
- The Second Affiliated Hospital & Yuying Children׳s Hospital of Wenzhou Medical University, Wenzhou 325027, China
| | - Ren-shan Ge
- The Second Affiliated Hospital & Yuying Children׳s Hospital of Wenzhou Medical University, Wenzhou 325027, China.
| |
Collapse
|